Oncoinvent ASA reported a 28% reduction in operating expenses for the first half of 2025 while advancing its Phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE